bluebird bio Insider Sells $114,000 in Stock (BLUE)
bluebird bio (NASDAQ:BLUE) Insider David Davidson unloaded 3,000 shares of the stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $38.00, for a total transaction of $114,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
bluebird bio (NASDAQ:BLUE) traded down 1.32% on Wednesday, hitting $38.03. 222,013 shares of the company’s stock traded hands. bluebird bio has a one year low of $17.03 and a one year high of $41.75. The stock’s 50-day moving average is $34.90 and its 200-day moving average is $28.14. The company’s market cap is $1.087 billion.
bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.06) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.45) by $0.39. The company had revenue of $6.30 million for the quarter, compared to the consensus estimate of $6.15 million. On average, analysts predict that bluebird bio will post $-1.69 earnings per share for the current fiscal year.
A number of research firms have recently commented on BLUE. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of bluebird bio in a research note on Wednesday, June 18th. They now have a $53.00 price target on the stock, up previously from $44.00. Separately, analysts at Wedbush raised their price target on shares of bluebird bio to $51.00 in a research note on Monday, June 16th. Finally, analysts at Piper Jaffray initiated coverage on shares of bluebird bio in a research note on Friday, June 13th. They set an “overweight” rating on the stock.
bluebird bio, Inc is a clinical-stage biotechnology company, the Company is focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.